AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival ("DFS") expected in H1 2025Poster presentation at the Society for Im ...

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

The Santa Clarita Valley Water Public Outreach and Legislation Committee will hold a meeting Thursday, Nov. 21, at 5:30 p.m., ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

at the 39 th Annual Meeting for the Society for Immunotherapy in Cancer (SITC2024), being held in Houston Texas from November 8 – 10, 2024. The late-breaking poster presentation focused on results ...

Yougov plc (GB:YOU) has released an update. YouGov PLC has released its Annual Report and Accounts for the fiscal year ending ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior year period. The increase in research and development expense was primarily ...

Courtesy of Sean D. Elliot The culmination of years of education and community engagement will shine front and center during ...

If you would like to be invited to future Annual General Meetings and have a say in the governance of Which?, helping us to make sure we keep consumers at the heart of everything we do, become an ...

Here we explore what the theory of general relativity is and how it affects ... she said during the 228 American Astronomical Society meeting in June 2016. Since then, scientists have begun ...